SOPHiA GENETICS (SOPH) Competitors $3.16 +0.03 (+0.96%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.14 -0.02 (-0.47%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SOPH vs. IMNM, NRIX, LENZ, MLYS, TRVI, SNDX, ORIC, URGN, NUVB, and SIONShould you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Immunome (IMNM), Nurix Therapeutics (NRIX), LENZ Therapeutics (LENZ), Mineralys Therapeutics (MLYS), Trevi Therapeutics (TRVI), Syndax Pharmaceuticals (SNDX), Oric Pharmaceuticals (ORIC), Urogen Pharma (URGN), Nuvation Bio (NUVB), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. SOPHiA GENETICS vs. Its Competitors Immunome Nurix Therapeutics LENZ Therapeutics Mineralys Therapeutics Trevi Therapeutics Syndax Pharmaceuticals Oric Pharmaceuticals Urogen Pharma Nuvation Bio Sionna Therapeutics SOPHiA GENETICS (NASDAQ:SOPH) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability. Do insiders and institutionals believe in SOPH or IMNM? 31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer SOPH or IMNM? In the previous week, SOPHiA GENETICS and SOPHiA GENETICS both had 2 articles in the media. Immunome's average media sentiment score of 1.18 beat SOPHiA GENETICS's score of -0.50 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Immunome 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend SOPH or IMNM? SOPHiA GENETICS presently has a consensus target price of $7.00, indicating a potential upside of 121.52%. Immunome has a consensus target price of $23.33, indicating a potential upside of 120.33%. Given SOPHiA GENETICS's higher probable upside, equities analysts clearly believe SOPHiA GENETICS is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, SOPH or IMNM? SOPHiA GENETICS has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Immunome has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Is SOPH or IMNM more profitable? SOPHiA GENETICS has a net margin of -98.51% compared to Immunome's net margin of -1,875.21%. SOPHiA GENETICS's return on equity of -63.47% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-98.51% -63.47% -40.06% Immunome -1,875.21%-71.65%-60.36% Which has preferable valuation and earnings, SOPH or IMNM? SOPHiA GENETICS has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$65.17M3.23-$62.49M-$1.00-3.16Immunome$9.04M101.93-$292.96M-$3.18-3.33 SummarySOPHiA GENETICS beats Immunome on 8 of the 15 factors compared between the two stocks. Get SOPHiA GENETICS News Delivered to You Automatically Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SOPH vs. The Competition Export to ExcelMetricSOPHiA GENETICSMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$208.73M$2.05B$5.48B$9.54BDividend YieldN/AN/A4.73%4.09%P/E Ratio-3.1633.7928.8623.83Price / Sales3.2328.84371.4466.13Price / CashN/A56.2135.4557.96Price / Book2.148.978.265.54Net Income-$62.49M-$62.31M$3.25B$259.28M7 Day Performance-12.22%-8.15%-3.75%-4.67%1 Month Performance3.95%1.83%4.27%4.37%1 Year Performance-28.99%21.01%25.85%17.91% SOPHiA GENETICS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SOPHSOPHiA GENETICS1.6335 of 5 stars$3.16+1.0%$7.00+121.5%-29.6%$208.73M$65.17M-3.16520Upcoming EarningsShort Interest ↑IMNMImmunome1.9944 of 5 stars$10.43-3.8%$23.33+123.8%-29.7%$908.84M$10.94M-3.2840News CoveragePositive NewsGap DownNRIXNurix Therapeutics2.6688 of 5 stars$11.82-0.9%$29.31+148.0%-48.6%$903.25M$88.38M-4.53300News CoverageAnalyst ForecastLENZLENZ Therapeutics1.6834 of 5 stars$31.29-0.7%$48.60+55.3%+21.7%$889.68MN/A-17.86110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMLYSMineralys Therapeutics2.5512 of 5 stars$13.61+0.0%$32.25+137.0%+13.4%$887.49MN/A-3.6528News CoverageInsider TradeTRVITrevi Therapeutics2.7757 of 5 stars$7.50-1.9%$20.88+178.4%+136.5%$886.15MN/A-16.7920News CoverageUpcoming EarningsShort Interest ↑SNDXSyndax Pharmaceuticals3.5573 of 5 stars$10.35+8.2%$34.10+229.5%-54.6%$879.17M$23.68M-2.65110Upcoming EarningsGap UpORICOric Pharmaceuticals4.5534 of 5 stars$10.41-6.9%$18.57+78.4%-4.6%$875.25MN/A-5.4580News CoveragePositive NewsURGNUrogen Pharma4.6177 of 5 stars$18.93+0.2%$32.86+73.6%+22.6%$873.18M$90.40M-5.94200News CoverageUpcoming EarningsInsider TradeGap DownNUVBNuvation Bio2.2444 of 5 stars$2.52-1.4%$7.17+185.0%-37.4%$848.96M$10.96M-1.0660News CoverageUpcoming EarningsSIONSionna TherapeuticsN/A$19.05-4.0%$38.50+102.1%N/A$840.49MN/A0.0035Lockup Expiration Related Companies and Tools Related Companies IMNM Alternatives NRIX Alternatives LENZ Alternatives MLYS Alternatives TRVI Alternatives SNDX Alternatives ORIC Alternatives URGN Alternatives NUVB Alternatives SION Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SOPH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
